(Finance) – Reduction for Applied Therapeuticswhich changed hands at a loss of 72.46%.
The FDA’s decision not to approve the drug govorestat for the treatment of galactosemia, a rare genetic metabolic disease, also weighs on shares.
The weekly analysis of the stock compared to Nasdaq 100 shows a lag behind the index in terms of relative strength of Applied Therapeuticswhich performs worse than the reference market.
Technical picture evidently deteriorating with controlling supports estimated in the USD 2.127 area. On the upside, however, a polarizing level of greater outflows is seen at 2.517. The worsening of Applied Therapeutics it is highlighted by the downward crossing of the 5-day moving average with the 34-day moving average. There are concrete possibilities of new declines for the target at 1.893 very soon.